OBJECTIVES: This study aimed to determine if CD31 is a novel marker of a circulating angio-vasculogenic cell population and to establish the cells' therapeutic effects on experimental ischemia. BACKGROUND: Emerging evidence suggested that therapeutic mechanisms underlying various bone marrow-derived cells are due to paracrine effects. Furthermore, the vasculogenic potential of these cells is under debate. CD31 is a well-known marker for endothelial cells but is also expressed in a fraction of peripheral blood (PB) mononuclear cells. METHODS: CD31(+) cells were isolated from human PB by magnetic-activated cell sorting. The gene expression profile was examined by deoxyribonucleic acid microarray and real-time reverse transcriptase polymerase chain reaction. Various in vitro endothelial differentiation or vasculogenic assays were conducted. Finally, cells were directly implanted into a mouse hind limb ischemia model to test angiogenic-vasculogenic and therapeutic effects. RESULTS: Fluorescent-activated cell sorter analysis revealed that PB-CD31(+) cells exhibited endothelial and hematopoietic stem/progenitor markers. CD31(+) cells had higher levels of expression of proangiogenic genes on microarray and real-time reverse transcriptase polymerase chain reaction and generated higher numbers of endothelial progenitor cells than CD31(-) cells did. CD31(+) cells spontaneously formed vascular tubelike structures and exhibited an endothelial cell phenotype in vitro. In a hind limb ischemia model, CD31(+) cell transplantation augmented blood perfusion and prevented limb loss. Both angiogenic cytokines and capillary density were increased, suggesting CD31(+) cells augmented neovascularization. CONCLUSIONS: CD31 is a novel marker that designates circulating angiogenic and vasculogenic cells. These cells are easily isolated from human PB and thus are a novel candidate for treatment of ischemic cardiovascular disease. Copyright (c) 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
OBJECTIVES: This study aimed to determine if CD31 is a novel marker of a circulating angio-vasculogenic cell population and to establish the cells' therapeutic effects on experimental ischemia. BACKGROUND: Emerging evidence suggested that therapeutic mechanisms underlying various bone marrow-derived cells are due to paracrine effects. Furthermore, the vasculogenic potential of these cells is under debate. CD31 is a well-known marker for endothelial cells but is also expressed in a fraction of peripheral blood (PB) mononuclear cells. METHODS:CD31(+) cells were isolated from human PB by magnetic-activated cell sorting. The gene expression profile was examined by deoxyribonucleic acid microarray and real-time reverse transcriptase polymerase chain reaction. Various in vitro endothelial differentiation or vasculogenic assays were conducted. Finally, cells were directly implanted into a mouse hind limb ischemia model to test angiogenic-vasculogenic and therapeutic effects. RESULTS: Fluorescent-activated cell sorter analysis revealed that PB-CD31(+) cells exhibited endothelial and hematopoietic stem/progenitor markers. CD31(+) cells had higher levels of expression of proangiogenic genes on microarray and real-time reverse transcriptase polymerase chain reaction and generated higher numbers of endothelial progenitor cells than CD31(-) cells did. CD31(+) cells spontaneously formed vascular tubelike structures and exhibited an endothelial cell phenotype in vitro. In a hind limb ischemia model, CD31(+) cell transplantation augmented blood perfusion and prevented limb loss. Both angiogenic cytokines and capillary density were increased, suggesting CD31(+) cells augmented neovascularization. CONCLUSIONS:CD31 is a novel marker that designates circulating angiogenic and vasculogenic cells. These cells are easily isolated from human PB and thus are a novel candidate for treatment of ischemic cardiovascular disease. Copyright (c) 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Authors: J Yamashita; H Itoh; M Hirashima; M Ogawa; S Nishikawa; T Yurugi; M Naito; K Nakao; S Nishikawa Journal: Nature Date: 2000-11-02 Impact factor: 49.962
Authors: H Kamihata; H Matsubara; T Nishiue; S Fujiyama; Y Tsutsumi; R Ozono; H Masaki; Y Mori; O Iba; E Tateishi; A Kosaki; S Shintani; T Murohara; T Imaizumi; T Iwasaka Journal: Circulation Date: 2001-08-28 Impact factor: 29.690
Authors: J K Chae; I Kim; S T Lim; M J Chung; W H Kim; H G Kim; J K Ko; G Y Koh Journal: Arterioscler Thromb Vasc Biol Date: 2000-12 Impact factor: 8.311
Authors: Maria B Grant; W Stratford May; Sergio Caballero; Gary A J Brown; Steven M Guthrie; Robert N Mames; Barry J Byrne; Timothy Vaught; Polyxenie E Spoerri; Ammon B Peck; Edward W Scott Journal: Nat Med Date: 2002-06 Impact factor: 53.440
Authors: Donald Lloyd-Jones; Robert Adams; Mercedes Carnethon; Giovanni De Simone; T Bruce Ferguson; Katherine Flegal; Earl Ford; Karen Furie; Alan Go; Kurt Greenlund; Nancy Haase; Susan Hailpern; Michael Ho; Virginia Howard; Brett Kissela; Steven Kittner; Daniel Lackland; Lynda Lisabeth; Ariane Marelli; Mary McDermott; James Meigs; Dariush Mozaffarian; Graham Nichol; Christopher O'Donnell; Veronique Roger; Wayne Rosamond; Ralph Sacco; Paul Sorlie; Randall Stafford; Julia Steinberger; Thomas Thom; Sylvia Wasserthiel-Smoller; Nathan Wong; Judith Wylie-Rosett; Yuling Hong Journal: Circulation Date: 2009-01-27 Impact factor: 29.690
Authors: Nathan T Jenkins; Rian Q Landers; Sunny R Thakkar; Xiaoxuan Fan; Michael D Brown; Steven J Prior; Espen E Spangenburg; James M Hagberg Journal: J Physiol Date: 2011-09-19 Impact factor: 5.182
Authors: Adinarayana Andukuri; Young-Doug Sohn; Chidinma P Anakwenze; Dong-Jin Lim; Brigitta C Brott; Young-Sup Yoon; Ho-Wook Jun Journal: Tissue Eng Part C Methods Date: 2012-12-19 Impact factor: 3.056
Authors: Yin Ge; Susan Cheng; Martin G Larson; Anahita Ghorbani; Roderick P Martin; Rachael J Klein; Christopher J O'Donnell; Ramachandran S Vasan; Stanley Y Shaw; Thomas J Wang; Kenneth S Cohen Journal: Atherosclerosis Date: 2013-04-22 Impact factor: 5.162